# Comment on Rossing et al. Nuances in Interpretation: Assessing the Interaction Between Semaglutide and MRAs in the FLOW Trial.

> PubMed lists PMID 41771053 in Diabetes care as Letter, with publication-date metadata of 2026-06-01 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41771053-semaglutide:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-08-13
- Source checked: 2026-08-13
- Published by PeptideScanner: 2026-08-13
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41771053-semaglutide/
- JSON record: https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-41771053-semaglutide-v1.json
- Content SHA-256: `2981974653b4c39ebb5cb144a115b1f4d0c3f09a0adb4354c8c7e92da8209147`

## Claims and source pins

### Headline

Comment on Rossing et al. Nuances in Interpretation: Assessing the Interaction Between Semaglutide and MRAs in the FLOW Trial. ([`pubmed-observation-pmid-41771053-2026-08-13-0e06086c0a13`](#source-pubmed-observation-pmid-41771053-2026-08-13-0e06086c0a13))

### Summary

PubMed lists PMID 41771053 in Diabetes care as Letter, with publication-date metadata of 2026-06-01 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41771053-2026-08-13-0e06086c0a13`](#source-pubmed-observation-pmid-41771053-2026-08-13-0e06086c0a13))

### Paragraph 1

PubMed lists PMID 41771053 in Diabetes care as Letter, with publication-date metadata of 2026-06-01 (day precision). PeptideScanner associated the retained record with the identity slug semaglutide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41771053-2026-08-13-0e06086c0a13`](#source-pubmed-observation-pmid-41771053-2026-08-13-0e06086c0a13))

### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41771053-2026-08-13-0e06086c0a13`](#source-pubmed-observation-pmid-41771053-2026-08-13-0e06086c0a13))

## Sources

<a id="source-pubmed-observation-pmid-41771053-2026-08-13-0e06086c0a13"></a>
- **Comment on Rossing et al. Nuances in Interpretation: Assessing the Interaction Between Semaglutide and MRAs in the FLOW Trial. · retained source version 1:2026-08-13:current:0e06086c0a136f12f9bda58fdf47cf9c839c1a040d1922d2f4520623be36dcbf** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41771053/) (`pubmed-observation-pmid-41771053-2026-08-13-0e06086c0a13`)

## Correction lineage

No correction is recorded for this version.

## Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

## Suggested citation

PeptideScanner. "Comment on Rossing et al. Nuances in Interpretation: Assessing the Interaction Between Semaglutide and MRAs in the FLOW Trial." Version 1, published 2026-08-13. https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-41771053-semaglutide-v1.json SHA-256: 2981974653b4c39ebb5cb144a115b1f4d0c3f09a0adb4354c8c7e92da8209147.